Ceribell, Inc. · NASDAQ:CBLL
Ceribell — Investor Presentation (January 2025)
28 slides from Ceribell's investor presentation, Jan 13, 2025
Slide 1: Corporate Presentation January 2025
Corporate Presentation January 2025
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, about the Company and its industry. These statements and the outcomes of the events they describe involve substantial risks, uncertainties and
Slide 3: A Novel, AI-Powered Point-of-Care EEG Platform for Acute Care
A Novel, AI-Powered Point-of-Care EEG Platform Designed to Optimize Care in the Acute Care Setting for Patients with Serious Neurological Conditions
Slide 4: Key Operating Highlights
Significant Potential Pipeline Market Key Operating Highlights 504 Active Accounts 86% FY 2024 YTD Gross Margin >$2B Total U.S. Estimated Annual Addressable Market ~$69M Annual Run-Rate Revenue 46% FY 2024 YTD YoY Revenue Growth * Data as of September 30, 2024
Slide 5: Seizures Are Highly Prevalent in Critically-Ill Patients, and Often Go Undiagnosed
PATIENT POPULATION ESTIMATED PREVALENCE OF SEIZURES1 Seizures Are Highly Prevalent in Critically-Ill Patients, and Often Go Undiagnosed Herman, S.T., et al. (2015) J Clin Neurophysiol. 32(2):87-95 Claassen, J., et al. (2004). Neurology. 62(10):1743-1748 Rudin, D., et al. (2011) Epilepsy Res. 96(1-2)
Slide 6: Time is Brain
Young, G. B., et al. (1996). Neurology, 47(1), 83–89. Lowenstein, D. H., et al. (1993). Neurology, 43(3 Pt 1), 483–488 "Time is Brain" TREATMENT DELAY (hrs) DURATION OF SEIZURE PATIENT RESPONSE RATE TO FIRST-LINE TREATMENT2 STATUS EPILEPTICUS ALL-CAUSE MORBIDITY & MORTALITY RATE1 >2.0
Slide 7: Medical Society Guidelines Recommend Timely EEG to Detect and Manage Seizures
Medical Society Guidelines Recommend Timely EEG to Detect and Manage Seizures Across Different Disease States 3. Green, T.L., et al. (2021) Stroke 52(5):e179-e197 4. Hoh, B.L., et al. (2023) Stroke 54(7): e314-e370 1. Brophy, G., et al. (2012) Neurocrit Care. 17(1):3-23 2. Panchal, et al. (2020) Cir
Slide 8: Overview of Conventional EEG and its Limitations in the Acute Care Setting
Overview of Conventional EEG and its Limitations in the Acute Care Setting Overview of EEG Requires EEG Technician Long Set-Up Process Large & Cumbersome Equipment Conventional EEG systems were not designed for the acute care setting Hardware & Access Challenges An EEG is a non-invasive tool used to
Slide 9: Conventional EEG is Not Suited for the Acute Care Setting and Leads to Long Delays
Clinical Reality: Conventional EEG is Not Suited for the Acute Care Setting and Leads to Long Delays Seizure Suspicion / EEG Order 1 EEG Arrival & Set-Up EEG Interpretation Hours or Days1,2,3 Gururangan, K., et al. (2016) Clinical Neurophysiology. 127(10):3335-3340. Maximum time from EEG order to ar
Slide 10: Wait, Treat, or Transfer? Delayed Access to EEG Leaves Clinicians with a Difficult Choice
Wait, Treat, or Transfer? Delayed Access to EEG Leaves Clinicians with a Difficult Choice Wait For EEG1 Unnecessary Intubation and/or Medication Increased Length of Stay Against Guidelines2,3,4 Treat Empirically Before EEG Delays in Treatment Increased Costs Transfer to Better Equipped Hospital 1. Y
Slide 11: Status Epilepticus Compared to Other Serious Conditions in the Acute Care Setting
Sepsis In-Hospital Stroke Cardiac Arrest Status Epilepticus In-Hospital Mortality Rate 16% 1 6-10% 2-4* 63% 5 18-30% 6 7** Average Age 67 8 65 9* 63 10 40 11 Hospital Protocol 12 Status Epilepticus Compared to Other Serious Conditions in the Acute Care Setting * Estimated/computed amounts **All-caus
Slide 12: Ceribell EEG System: Suspicion to Diagnosis in Minutes
Ceribell EEG System: Suspicion to Diagnosis in Minutes, Enabling Earlier & More Accurate Treatment Early detection ~5 Minutes to Set Up 1 EEG Arrival & Set-Up 2 EEG Interpretation 3 by any trained, non-specialized healthcare professional 1,2,3 System The Continuous monitoring Seizure Suspicion / EEG
Slide 13: The Ceribell System
System The Combining highly portable, simple-to-use and rapidly deployable hardware and AI-powered algorithms EEG Portal Headband Recorder CAUTION: Device does not substitute for EEG review by a qualified clinician. Before use, the manual should be reviewed for indications, contraindications, warnin
Slide 14: Clarity: Our Proprietary AI-Powered Seizure Detection Algorithm
Clarity: Our Proprietary AI-Powered Seizure Detection Algorithm Bed-side Alerts Real-time feedback on response to medication Provides seizure burden to facilitate EEG reading for neurologists CAUTION: Device does not substitute for EEG review by a qualified clinician. Before use, the manual should b
Slide 15: Ceribell Supports Precise Patient Care for SE
Ceribell Supports Precise Patient Care for SE: Expediting Diagnosis and Continuously Monitoring Seizure Burden CAUTION: Device does not substitute for EEG review by a qualified clinician. Before use, the manual should be reviewed for indications, contraindications, warnings, precautions, potential a
Slide 16: SAFER-EEG Clinical Study: ICU Patient Outcomes
SAFER-EEG Clinical Study: ICU Patient Outcomes at Sites w/ Conventional EEG and Ceribell1 Desai, M., et al. (2024) Neurocrit Care. The Modified Rankin Scale (mRS) is a 6-point disability scale with possible scores ranging from 0 to 5. 0 is healthy and 5 is severe disability. A separate category of 6
Slide 17: Validated Cost Savings
Validated Cost Savings 1. Wright, N., et al. (2021) EMJ. 38(12):923-926 2. Eberhard, E., et al. (2023) J Neurosci Nurs. 55(5):157-163 3. Ney, J.P., et al. (2021) J Med Econ. 24(1):318-327 4. Madill et al. (2022) Epileptic Disord 24 (3): 507-516 5. Vespa, P., et al. (2020) Crit Care Med. 48(9):1249-
Slide 18: High Barriers To Entry
High Barriers To Entry Patent portfolio as of June 30, 2024 1. As of June 30, 2024 13 issued US patents Large acute care EEG database (800,000 hours)1 enabled by our hardware Detailed labeling by epileptologists EEG signal processing and algorithm knowhow Established and supportive clinician base Wo
Slide 19: Business Model: Two Sources of Recurring Revenue
Business Model: Two Sources of Recurring Revenue + + Recorder Capital Portal SaaS AI Algorithm SaaS Single Use Headband Disposable ~25% SaaS (monthly subscription)1 ~$5,000 list price ~75% Disposable (fee per Headband)1 ~$800 list price Recurring Revenue TM 1. From Q1 2022 to Q2 2024
Slide 20: Advantages of Ceribell's Business Model
Advantages of Ceribell’s Business Model Highly Sticky Business Model 1 Low attrition rate Consistent reorders Strong competitive position and high barriers to entry Bifurcated Sales Force Driving Growth and Retention 2 Territory Managers focusing on new account acquisition and onboarding Clinical Ac
Slide 21: Rapid Commercial Expansion & Projectable Business Model
Rapid Commercial Expansion & Projectable Business Model Consistent sequential quarterly total revenue growth fueled primarily by consistent growth in active account base and utilization per active account ($ in million)
Slide 22: Continued Momentum on Account Acquisition
Continued Momentum on Account Acquisition Key Growth Drivers: Increase Active Account Base & Drive Utilization Active Accounts 504 * As of September 30, 2024 Significant Acceleration in Same Store Growth Utilization per Active Account Launched Utilization Strategy (July 2021)
Slide 23: Significant, Highly Under-penetrated Total Addressable Market
Significant, Highly Under-penetrated Total Addressable Market Internal analysis of National Inpatient Sample and National Emergency Department Sample data Per Definitive Healthcare History of Prior Seizure; No Return to Baseline Cardiac Arrest after ROSC Subarachnoid Hemorrhage Intracerebral Hemorrh
Slide 24: Ceribell Growth Strategies
Drive Utilization of the Ceribell System within Existing Customer Base Increase Adoption of the Ceribell System in New Accounts Continue to Drive Awareness of Seizures in the Acute Care Setting Invest in Growing our Base of Clinical Evidence further Continue to Improve and Innovate the Ceribell Syst
Slide 25: Long-Term Vision: Building an EEG Platform for Various Indications and Settings
Ceribell’s Long-Term Vision: Building an EEG Platform for Various Indications and Settings NOW MEDIUM TERM LONG TERM Seizure Management in the Acute Care Setting Make EEG a new Vital Sign in Acute Care Develop Solutions for Use Beyond the Acute Care Setting Become Standard of Care Indication Expansi
Slide 26: 2025 Areas of Focus
2025 Areas of Focus NOW Seizure Management in the Acute Care Setting Make EEG a new Vital Sign in Acute Care MEDIUM TERM Commercial Expand active account base and drive utilization to further advance market leadership Further penetrate VA opportunity following receipt of Authority to Operate from th
Slide 27: Ceribell Investment Highlights
1 Unique platform technology representing a paradigm shift in brain monitoring in the acute care setting 2 Compelling clinical and economic benefits for key stakeholders, with support from robust body of clinical and real-world evidence 3 Large >$2B estimated addressable market opportunity with a si
Slide 28: ceribell
ceribell ee ee